Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KYMR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| KT-621 | Atopic Dermatitis | Phase 2 · NCT07217015 | Active not recruiting |
| SAR444656 (KT-474) | Atopic Dermatitis | Phase 2 · NCT06058156 | Terminated |
| MDM2 Degrader KT-253 | Myeloid Malignancies | Phase 1 · NCT05775406 | Completed |
| Lirodegimod (KT-333) | Non Hodgkin Lymphoma (NHL) | Phase 1 · NCT05225584 | Completed |
| Zomiradomide (KT-413) | Non Hodgkin Lymphoma | Phase 1 · NCT05233033 | Completed |
| KT-474 | Healthy Volunteer | Phase 1 · NCT04772885 | Completed |
| KT-579 | Healthy Participants | Phase 1 · NCT07412288 | Completed |
| SAR447971 | Hidradenitis | Phase 1 · NCT07629336 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KYMR holds $1.6B in cash and short-term investments (as of Sep 30, 2026) and burns about $66M/quarter from operations, an estimated runway of 74.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into 2029, beyond multiple clinical inflection points in our pipeline.10-Q, Oct 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KYMR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 11,681,450 | 13.68% | 2026-03-31 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 8,873,588 | 10.39% | 2026-08-31 |
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 8,676,797 | 10.16% | 2025-12-09 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 5,460,257 | 6.40% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,450,286 | 6.38% | 2026-09-30 |
| Nello Mainolfi Chief Executive Officer, Director · +60,000 options |
Insider | 666,568 | 0.78% | 2026-10-01 |
| Bruce Booth Director · +34,195 options |
Insider | 462,856 | 0.54% | 2026-06-26 |
| BVF PARTNERS L P/IL Director · +150,055 options |
Insider | 318,910 | 0.37% | 2026-06-26 |
| Bruce N. Jacobs Chief Financial Officer |
Insider | 244,883 | 0.29% | 2026-06-30 |
| Brian Adams Chief Legal Officer |
Insider | 50,254 | 0.06% | 2026-09-04 |
| Noah Goodman Chief Business Officer · +90,000 options |
Insider | 47,179 | 0.06% | 2026-07-01 |
| Jeremy G Chadwick Chief Operating Officer · +103,697 options |
Insider | 44,018 | 0.05% | 2026-05-26 |
Share count 85,371,397 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYMR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →